Treatment with PSGL-1-targeted BTZ-loaded liposomes resulted in a significant reduction in tumor progression (approximately three orders of magnitude) compared to non-targeted empty liposome controls; PSGL-1-targeted multi-drug liposomes significantly improved the antitumor effect and reduced tumor progression by an order of magnitude compared to the PSGL-1-targeted BTZ-loaded liposomes (Fig. 7aiii). This evidence concerns the gene SELPLG and neoplasm.